1.1533
price up icon2.65%   0.0233
 
loading
Precedente Chiudi:
$1.13
Aprire:
$1.13
Volume 24 ore:
358.09K
Relative Volume:
0.33
Capitalizzazione di mercato:
$16.51M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.8737
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
-5.31%
1M Prestazione:
+39.71%
6M Prestazione:
+52.41%
1 anno Prestazione:
+27.57%
Intervallo 1D:
Value
$1.11
$1.18
Intervallo di 1 settimana:
Value
$1.11
$1.3399
Portata 52W:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Nome
Hoth Therapeutics Inc
Name
Telefono
(646)756-2997
Name
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
HOTH's Discussions on Twitter

Confronta HOTH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
1.15 16.51M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.23 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
546.34 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.32 28.51B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2019-10-15 Iniziato The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie

pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India

Jun 12, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

First-Ever Treatment for EGFR Cancer Therapy Skin Toxicities: Experts Review Game-Changing Clinical Data - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World

Jun 04, 2025
pulisher
May 31, 2025

Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen - Defense World

May 31, 2025
pulisher
May 28, 2025

Hoth Therapeutics (NASDAQ:HOTH) Shares Up 0.7% – What’s Next? - Defense World

May 28, 2025
pulisher
May 16, 2025

Hoth Therapeutics Faces Nasdaq Compliance Challenge - TipRanks

May 16, 2025
pulisher
May 13, 2025

Hoth Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 12, 2025

HOTH THERAPEUTICS Earnings Results: $HOTH Reports Quarterly Earnings - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Hoth Therapeutics reports promising HT-KIT preclinical results By Investing.com - Investing.com Canada

May 12, 2025
pulisher
May 12, 2025

Hoth Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PR Newswire

May 12, 2025
pulisher
May 12, 2025

Hoth Therapeutics reports promising HT-KIT preclinical results - Investing.com Australia

May 12, 2025
pulisher
May 11, 2025

Hoth Therapeutics (HOTH) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Purchases 13,038 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) - Defense World

May 05, 2025
pulisher
May 02, 2025

Hoth Therapeutics confirms patent application fee payment By Investing.com - Investing.com Nigeria

May 02, 2025
pulisher
May 02, 2025

Hoth Therapeutics confirms patent application fee payment - Investing.com

May 02, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models - Curetoday

Apr 27, 2025
pulisher
Apr 21, 2025

Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT GeneExpands Global IP in Precision Oncology Platform - PR Newswire

Apr 17, 2025
pulisher
Apr 16, 2025

Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - marketscreener.com

Apr 15, 2025

Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.57
price up icon 0.37%
$35.91
price up icon 0.13%
$21.11
price up icon 2.33%
$100.34
price up icon 0.90%
$106.37
price down icon 0.26%
biotechnology ONC
$242.46
price up icon 0.52%
Capitalizzazione:     |  Volume (24 ore):